We report a patient with hemifacial spasm of the right hemiface and ipsilateral glaucomatous optic neuropathy. No risk factors were found to explain the unilateral glaucoma. Ocular pressure readings were always within normal range.

Goldmann H: Das Glaukom; in Amsler M, Brückner A, Franceschetti A, Goldmann H, Streit EB (Hrsg): Lehrbuch der Augenheilkunde. Basel, Karger, 1954, p 398.
Flammer J, Gasser P, Prünte C, Yao K: The probable involvement of factors other than ocular pressure in the pathogenesis of glaucoma; in Drance SM, van Buskirk EM, Neufeld AM (eds): Pharmacology of Glaucoma. Baltimore, Williams & Wilkins, 1992, pp 273–283.
Flammer J: The vascular concept of glaucoma. Surv Ophthalmol 1994;38(suppl):3–6.
Haefliger IO, Flammer J, Lüscher T: Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci 1992;33:2340–2343.
Haefliger IO, Meyer P, Flammer J, Lüscher TF: The vascular endothelium as a regulator of the circulation of the eye: A new concept in ophthalmology. Surv Ophthalmol 1994;39:123–132.
Wax MB, Tezel G: Anti-Ro/SS-A positive and heat shock protein antibodies in patients with normal-pressure glaucoma. Am J Ophthalmol 1998;125:145–157.
Cartwright M, Grajewski AL, Friedberg M: Immune-related disease and normal tension glaucoma. Arch Ophthalmol 1992;110:500–502.
Wax MB, Barret DA, Pestronk A: Increased incidence of paraproteinemia and autoantibodies in patients with normal-tension glaucoma. Am J Ophthalmol 1994;117:561–668.
van Buskirk EM, Ciolli GA: Glaucomatous optic neuropathy. Am J Ophthalmol 1992;113:447.
Burde RM, Savino PJ, Trobe JD: Clinical decisions in neuro-ophthalmology. St. Louis, Mosby/Year Book, 1992.
Janetta PJ: Observations of trigeminal neuralgia, hemifacial spasm, acoustic nerve dysfunction and glossopharyngeal neuralgia: Definitive microsurgical treatment and results in 117 patients. Neurochirurgia 1977;20:145–154.
Miller D: Pressure of the lid of the eye. Arch Ophthalmol 1967;78:328–330.
Coleman J, Trokel S: Direct-recorded intraocular pressure variations in a human subject. Arch Ophthalmol 1969;82:637–640.
Dutton JJ: Botulinum-A toxin in the treatment of craniocervical muscle spasms: Short and long-term, local and systemic effects. Surv Ophthalmol 1996;41:51–56.
Assessment: Subcommittee of the American Academy of Neurology. The clinical usefulness of botulinum toxin-A in treating neurologic disorders. Neurology 1990;40:1332–1336.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.